^
BIOMARKER:

BRCA2 mutation

i
Other names: BRCA2, BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, Breast cancer 2, early onset




Show legend

Include preclinical:
Triple Negative Breast Cancer
Ovarian Cancer
Prostate Cancer
Breast Cancer
HER2 Negative Breast Cancer
Pancreatic Adenocarcinoma
Pancreatic Cancer
Hormone Receptor Positive Breast Cancer
Solid Tumor
Fallopian Tube Cancer
Peritoneal Cancer
Pancreatic Ductal Adenocarcinoma
Biliary Tract Cancer
Non Small Cell Lung Cancer
Ovarian Serous Adenocarcinoma
Colon Cancer
Lung Adenocarcinoma
Colorectal Cancer
Lung Cancer
Uterine Corpus Leiomyosarcoma
Urothelial Cancer
Endometrial Cancer
Cholangiocarcinoma
Bladder Cancer
Germ Cell Tumors
Oral Cancer
Malignant Pleural Mesothelioma
Gastrointestinal Cancer
Head and Neck Cancer
Renal Cell Carcinoma
Esophageal Squamous Cell Carcinoma
Immunotherapy
CPB
PARP inhibitor
FOLFIRINOX
PARP inhibitor + Src kinase inhibitor
Androgen receptor inhibitor
Immunotherapy + PARP inhibitor
CDK4 inhibitor + CDK6 inhibitor
FOLFOX
PD-L1 inhibitor + PARP inhibitor
GnRH stimulant
olaparib
cisplatin + gemcitabine
carboplatin
vinorelbine tartrate
gemcitabine
eribulin mesylate
paclitaxel
pegylated liposomal doxorubicin
capecitabine
doxorubicin hydrochloride
rucaparib
ABT-888
talazoparib
niraparib
CX-5461
avelumab + talazoparib
carboplatin + paclitaxel
pamiparib
BSI 201
olaparib + capivasertib
avelumab
bevacizumab + olaparib
IMP4297
pembrolizumab
ribociclib
IDE161
cisplatin
olaparib + durvalumab
rivoceranib + fluzoparib
AZD1775
tislelizumab + pamiparib
fluzoparib
olaparib + cediranib
olaparib + AZD6738
JPI-547
olaparib + gefitinib
atezolizumab
docetaxel
bevacizumab + olaparib + durvalumab
olaparib + tremelimumab
SC10914
olaparib + durvalumab + tremelimumab
durvalumab
lurbinectedin
ACR-368
pembrolizumab + olaparib
pembrolizumab + niraparib
oxaliplatin
nivolumab
abiraterone/niraparib
bevacizumab + niraparib + dostarlimab-gxly
olaparib + AZD1775
melphalan
temozolomide + ABT-888
NOV 1401
anlotinib + niraparib
olaparib + ACR-368
olaparib + AT13387
rucaparib + copanlisib
ipilimumab + niraparib
talazoparib + PF-05212384
nivolumab + rucaparib
enzalutamide capsule
carboplatin + pegylated liposomal doxorubicin
pegylated liposomal doxorubicin + trabectedin
gemcitabine + albumin-bound paclitaxel
tocilizumab
nivolumab + ipilimumab
carboplatin + docetaxel
camrelizumab
olaparib + sintilimab
niraparib + dostarlimab-gxly
trabectedin
TQB3823
nedaplatin
ACR-368 + LY3023414
olaparib + APG-1387
bevacizumab
fulvestrant + anastrozole
gemcitabine + eribulin mesylate
olaparib + RG6614
talazoparib + LY294002
ART558
niraparib + AZD1775
osimertinib
sintilimab
olaparib + palbociclib
BGB324
palbociclib
PARP inhibitor + RK-33